TY - JOUR
T1 - Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients
T2 - A nationwide prospective cohort from the French Sarcoma Group
AU - Penel, Nicolas
AU - Le Cesne, Axel
AU - Bonvalot, Sylvie
AU - Giraud, Antoine
AU - Bompas, Emmanuelle
AU - Rios, Maria
AU - Salas, Sébastien
AU - Isambert, Nicolas
AU - Boudou-Rouquette, Pascaline
AU - Honore, Charles
AU - Italiano, Antoine
AU - Ray-Coquard, Isabelle
AU - Piperno-Neumann, Sophie
AU - Gouin, François
AU - Bertucci, François
AU - Ryckewaert, Thomas
AU - Kurtz, Jean Emmanuel
AU - Ducimetiere, Françoise
AU - Coindre, Jean Michel
AU - Blay, Jean Yves
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose The outcome of desmoid-type fibromatosis (DTF) is unpredictable. Currently, a wait-and-see approach tends to replace large en bloc resection as the first therapeutic approach. Nevertheless, there are no validated factors to guide the treatment choice. Method We conducted a prospective study of 771 confirmed cases of DTF. We analysed event-free survival (EFS) based on the occurrence of relapse after surgery, progressive disease during the wait-and-see approach, or change in therapeutic strategy. Identification of prognostic factors was performed using classical methods (log-rank test and Cox model). Results Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415). In univariate analysis, two prognostic factors significantly influenced the outcome: the nature of diagnostic sampling (p = 0.466) and primary location (p = 0.0001). The 2-year EFS was only 32% after open biopsy. The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001). Conclusion The location of DTF is a major prognostic factor for EFS. If these findings are confirmed by independent analysis, personalised management of DTF must consider this easily obtained parameter.
AB - Purpose The outcome of desmoid-type fibromatosis (DTF) is unpredictable. Currently, a wait-and-see approach tends to replace large en bloc resection as the first therapeutic approach. Nevertheless, there are no validated factors to guide the treatment choice. Method We conducted a prospective study of 771 confirmed cases of DTF. We analysed event-free survival (EFS) based on the occurrence of relapse after surgery, progressive disease during the wait-and-see approach, or change in therapeutic strategy. Identification of prognostic factors was performed using classical methods (log-rank test and Cox model). Results Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415). In univariate analysis, two prognostic factors significantly influenced the outcome: the nature of diagnostic sampling (p = 0.466) and primary location (p = 0.0001). The 2-year EFS was only 32% after open biopsy. The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001). Conclusion The location of DTF is a major prognostic factor for EFS. If these findings are confirmed by independent analysis, personalised management of DTF must consider this easily obtained parameter.
KW - Desmoid-type fibomatosis
KW - Nationwide cohort
KW - Prognostic factors
KW - Surgery
KW - Wait and see
UR - http://www.scopus.com/inward/record.url?scp=85024854507&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2017.06.017
DO - 10.1016/j.ejca.2017.06.017
M3 - Article
C2 - 28735069
AN - SCOPUS:85024854507
SN - 0959-8049
VL - 83
SP - 125
EP - 131
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -